Professor Ingo Hilgendorf

Professor Ingo Hilgendorf

University of Freiburg, Freiburg (Germany)

Member of:

Professor Hilgendorf works as an interventional cardiologist and deputy medical director at Germany’s largest University Heart Center at Freiburg-Bad Krozingen. He leads the high-risk outpatient clinic and engages in clinical trials in the field of lipid therapy, heart failure, immunomodulation, and coronary and structural heart disease. Following his postdoctoral training at the MGH Center for Systems Biology, Boston, MA, USA, he established his own research group in Freiburg, Germany, studying the role of the innate and adaptive immune system in cardiovascular disease and the impact of traditional and non-traditional risk factors. Based on his seminal work, Ingo Hilgendorf was appointed Heisenberg Professor for Immunocardiology at the University of Freiburg, Germany.

Presentations Articles

The physician`s perspective: what prevents us from keeping LDL-C lower for longer? Who are the patients that need more help?

Event: ESC Congress 2022

Topic: Lipid-Lowering Agents

Session: Lower for longer: reframing the clinical goal for LDL-C. The lower the better is no longer enough

Access

NLRP3 mediates atheromatous plaque macrophage proliferation

Event: ESC Congress 2022

Topic: Leukocytes, Inflammation, Immunity

Session: Atherosclerosis and inflammation

Access

Incorporating Lp(a) into risk classification for patients with ASCVD.

Event: ESC Congress 2022

Topic: Cardiovascular Risk Assessment

Session: Uncovering the hidden risk: why lipoprotein(a) testing is crucial

Access

Lipid im- and exporters differentially determine macrophage turnover in the plaque

Event: ESC Congress 2017

Topic: Lipids

Session: Lipids, cardiac pathology

Access

SYK inhibitor fostamtinib protects from early but not established atherosclerosis when local macrophage proliferation dominates lesion turnover

Event: ESC Congress 2016

Topic: Atherosclerosis

Session: Best Posters in atherosclerosis

Access

ESC 365 is supported by

Explore sponsored resources

Professor Ingo Hilgendorf

Biography

Contributor content

The physician`s perspective: what prevents us from keeping LDL-C lower for longer? Who are the patients that need more help?

NLRP3 mediates atheromatous plaque macrophage proliferation

Incorporating Lp(a) into risk classification for patients with ASCVD.

Lipid im- and exporters differentially determine macrophage turnover in the plaque

SYK inhibitor fostamtinib protects from early but not established atherosclerosis when local macrophage proliferation dominates lesion turnover

ESC 365 is supported by